JINYU(SH:600201)2021-08-26 16:00Financial Performance - The company's operating revenue for the first half of 2021 was ¥840,429,279.75, representing a 34.61% increase compared to ¥624,355,493.78 in the same period last year[20]. - The net profit attributable to shareholders for the first half of 2021 was ¥257,942,857.27, up 41.38% from ¥182,445,680.86 in the previous year[20]. - The net profit after deducting non-recurring gains and losses was ¥251,503,376.55, reflecting a 39.61% increase from ¥180,151,927.28 in the same period last year[20]. - Basic earnings per share for the first half of 2021 were ¥0.23, a 43.75% increase from ¥0.16 in the same period last year[20]. - The weighted average return on net assets increased by 1.19 percentage points to 5.04% from 3.85% in the previous year[20]. - The company achieved operating revenue of 840 million yuan, a year-on-year increase of 34.61%; net profit attributable to shareholders was 258 million yuan, up 41.38% year-on-year[39]. - The company reported a net profit for the first half of 2021 reached CNY 264,861,106, an increase of 39.2% compared to CNY 190,186,198 in the same period of 2020[123]. - The total comprehensive income for the current period amounted to CNY 258,150,823.52, which includes a net profit of CNY 257,942,857.27[144]. Cash Flow and Assets - The net cash flow from operating activities decreased by 24.84% to ¥80,034,359.97 from ¥106,483,123.49 in the previous year[20]. - The total assets at the end of the reporting period were ¥6,347,505,359.72, a 1.10% increase from ¥6,278,282,683.24 at the end of the previous year[20]. - The company's total assets as of June 30, 2021, amounted to RMB 4,649,282,287.29, a slight increase from RMB 4,623,475,524.00 at the end of 2020[117]. - Cash and cash equivalents decreased to RMB 729,472,606.15 as of June 30, 2021, from RMB 840,062,902.98 at the end of 2020, a decline of 13.2%[114]. - The total equity of the company increased to RMB 4,493,832,732.79 as of June 30, 2021, compared to RMB 4,308,367,634.85 at the end of 2020, reflecting a growth of 4.3%[119]. Research and Development - R&D investment reached 84.19 million yuan, accounting for 10.02% of operating revenue, with significant progress in multiple research paths for African swine fever vaccines[39]. - The company has established over ten R&D platforms, including pathogen diagnosis, cell technology, and gene engineering expression platforms, enhancing its research capabilities and industry position[36]. - The company has developed a dedicated R&D team for various vaccines, including African swine fever and brucellosis vaccines, covering multiple vaccine development technologies[36]. - The company reported investment income of CNY 298,143,980.92 for the first half of 2021, significantly higher than CNY 189,002,385.62 in the previous year, marking a growth of 57.8%[125]. Market Position and Strategy - The company focuses on the development of animal vaccines, maintaining a leading market share in foot-and-mouth disease vaccines[26]. - The company is actively promoting the internationalization of its products, with a steady increase in market share in the vaccine procurement sector[26]. - The company operates a "sales-driven production" model, coordinating production and sales plans across departments to optimize resource allocation[32]. - The company has established a joint venture with a Japanese pharmaceutical company to develop and market pet vaccines in China, tapping into the domestic pet health market[33]. Environmental and Social Responsibility - Jin Yu Bao Ling invested CNY 92.34 million in environmental protection measures during the construction of its biotechnology park[71]. - The wastewater treatment plant at Jin Yu Bao Ling has a designed capacity of 1,000 m³/d, utilizing a "pulse anaerobic + MBR aerobic" treatment process[71]. - The company has established an EHS department and implemented various environmental management systems, including ISO14001 and ISO50001, to enhance pollution control and resource utilization[84]. - The company reported no exceedance of pollutant discharge standards in its operations[67]. Shareholder Information - The total number of ordinary shareholders reached 59,570 by the end of the reporting period[95]. - The top ten shareholders hold a total of 189,552,579 shares, representing 16.83% of the total shares outstanding[97]. - The report indicates that 90,000 shares from the equity incentive plan will become tradable on November 30, 2021, for shareholder Li Rong[100]. - The company has implemented an equity incentive plan that includes various shareholders with specific trading restrictions and release dates[100]. Risks and Challenges - The company faced risks including market competition, product development uncertainties, and potential regulatory changes impacting the veterinary vaccine sector[54]. - The company has outlined potential risks in the "Management Discussion and Analysis" section of the report[7].